• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

    11/14/24 4:05:18 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELVN alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Enliven Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    29337E102
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,100,000*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,100,000*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,100,000*

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.7%*

     
    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

    *See Item 4 for additional information.

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,100,000*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,100,000*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,100,000*

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.7%*

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

    *See Item 4 for additional information.

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    Item 1. (a) Name of Issuer
       
      Enliven Therapeutics, Inc. (the “Issuer”)
       
    Item 1. (b) Address of Issuer’s Principal Executive Offices
       
      6200 Lookout Road, Boulder, CO 80301
       
    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.
       
    Item 2. (d) Title of Class of Securities
       
      Common Stock, par value $0.001 per share (the “Common Stock”)
       
    Item 2. (e) CUSIP No.:
       
      29337E102
       
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:
       
      N/A

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    Item 4. Ownership
       
      As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:
       
      (a) Amount Beneficially Owned: 4,100,000*
      (b) Percent of Class: 8.7%*
      (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 4,100,000*
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 4,100,000*

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:
     
    (a) Amount Beneficially Owned: 4,100,000*
    (b) Percent of Class: 8.7%*
    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 4,100,000*
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 4,100,000*

     

    *The Firm is the investment manager to Commodore Master. As of September 30, 2024, the Firm may be deemed to beneficially own an aggregate of 4,100,000 shares of Common Stock of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 47,254,280 shares of Common Stock reported as issued and outstanding as of September 30, 2024 in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 13, 2024.

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person
       
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group
       
      Not Applicable.
       
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

    1. Joint Filing Agreement dated as of April 24, 2023, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on April 24, 2023).

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Commodore Capital LP  
       
    By: /s/ Michael Kramarz  
    Michael Kramarz, Managing Partner  
       
    Commodore Capital Master LP  
       
    By: /s/ Michael Kramarz  
    Michael Kramarz, Authorized Signatory  

     

     

     

    Get the next $ELVN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ELVN

    DatePrice TargetRatingAnalyst
    6/16/2025$37.00Buy
    Goldman
    12/13/2024$42.00Buy
    BTIG Research
    9/9/2024$37.00Buy
    H.C. Wainwright
    6/11/2024$32.00Outperform
    Robert W. Baird
    4/9/2024$34.00Buy
    Mizuho
    3/29/2023$27.00Buy
    Jefferies
    3/3/2023Outperform
    TD Cowen
    More analyst ratings

    $ELVN
    SEC Filings

    See more
    • SEC Form 8-K filed by Enliven Therapeutics Inc.

      8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

      6/25/25 4:05:18 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Enliven Therapeutics Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      6/20/25 4:02:28 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Enliven Therapeutics Inc.

      SCHEDULE 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      6/17/25 5:30:13 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

      BOULDER, Colo., June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant, which represent

      6/16/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

      BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,780,263 shares of Enliven's common stock at a price to the public of $19.659 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less t

      6/13/25 9:30:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

      BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven

      6/13/25 6:10:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $67,956 worth of shares (3,250 units at $20.91) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      7/1/25 4:42:33 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $267,458 worth of shares (12,500 units at $21.40) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      6/24/25 5:36:21 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Kintz Samuel sold $277,292 worth of shares (12,500 units at $22.18) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      6/18/25 6:22:48 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Financials

    Live finance-specific insights

    See more
    • Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

      Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff Enliven will host a webcast and conference call today, June 13, at 1:30 p.m. ET BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutic

      6/13/25 6:02:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

      Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled Enliven to host a webcast and conference call following the oral presentation at EHA on Friday, June 13, at 1:30 p.m. ET Strong balance sheet with $290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027 BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clini

      5/14/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

      Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage bi

      5/14/25 9:56:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Enliven Therapeutics with a new price target

      Goldman initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

      6/16/25 7:46:51 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Enliven Therapeutics with a new price target

      BTIG Research initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $42.00

      12/13/24 7:38:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Enliven Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

      9/9/24 7:29:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

      BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e

      4/9/24 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:48:35 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:46:11 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 4:24:01 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care